Vericel Corp (VCEL)
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Vericel Corporation
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 51.79 | 54.64 | 50.76 | 54.62 | 1,616,567 |
| Nov 5, 2026 | 50.54 | 55.60 | 49.00 | 51.78 | 2,682,494 |
| Nov 4, 2026 | 42.07 | 45.98 | 42.07 | 45.48 | 1,807,628 |
| Nov 3, 2026 | 40.52 | 41.50 | 40.28 | 41.09 | 635,185 |
| Nov 2, 2026 | 40.29 | 40.88 | 39.44 | 40.51 | 684,368 |
| Oct 30, 2026 | 43.02 | 43.02 | 40.01 | 40.26 | 598,736 |
| Oct 29, 2026 | 41.99 | 43.05 | 41.48 | 42.91 | 544,832 |
| Oct 28, 2026 | 43.05 | 43.50 | 40.59 | 41.09 | 680,186 |
| Oct 27, 2026 | 43.04 | 43.74 | 42.65 | 43.27 | 558,367 |
| Oct 26, 2026 | 42.73 | 43.83 | 42.30 | 43.04 | 634,753 |
| Oct 23, 2026 | 42.99 | 43.00 | 41.75 | 42.53 | 494,731 |
| Oct 22, 2026 | 41.21 | 43.01 | 40.02 | 42.97 | 604,939 |
| Oct 21, 2026 | 40.00 | 41.04 | 40.00 | 40.94 | 431,999 |
| Oct 20, 2026 | 40.81 | 41.02 | 39.97 | 40.58 | 475,256 |
| Oct 19, 2026 | 40.36 | 40.95 | 40.04 | 40.37 | 334,246 |
| Oct 16, 2026 | 41.07 | 41.55 | 39.71 | 40.13 | 737,148 |
| Oct 15, 2026 | 40.77 | 41.60 | 40.26 | 41.02 | 601,208 |
| Oct 14, 2026 | 39.90 | 40.31 | 39.59 | 40.25 | 384,553 |
| Oct 13, 2026 | 40.62 | 40.77 | 39.99 | 40.30 | 511,740 |
| Oct 12, 2026 | 40.30 | 40.81 | 39.00 | 40.62 | 432,877 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 ZERBE ROBERT L MD | Director | Option Exercise | 2.5K | $32.6K | Nov 5, 2026 |
| ZERBE ROBERT L MD | Director | Option Exercise | 500 | $6.5K | Nov 5, 2026 |
| ZERBE ROBERT L MD | Director | Sale | 2.5K | $129.2K | Nov 5, 2026 |
 Flynn Sean C. | Chief Legal Officer | Option Exercise | 15.0K | -- | Nov 5, 2026 |
 SIEGAL JONATHAN | Principal Accounting Officer | Option Exercise | 1.5K | -- | Nov 5, 2026 |
| Flynn Sean C. | Chief Legal Officer | Sale | 15.0K | $778.8K | Nov 5, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
BlackRock, Inc. | 8.1M | 15.9% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Apr 2025 | 7.6M | 14.8% | 13G |
STATE STREET CORP | 3.3M | 6.5% | 13F |
STATE STREET CORPORATION · also on 13F· may incl. warrants· filed Nov 2025 | 2.8M | 5.5% | 13G |
CONGRESS ASSET MANAGEMENT CO | 2.6M | 5.0% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 2.3M | 4.4% | 13F |
Aberdeen Group plc | 2.2M | 4.2% | 13F |
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2.0M | 3.8% | 13F |
BNP Paribas Asset Management Holding S.A. | 1.6M | 3.2% | 13F |
Conestoga Capital Advisors, LLC | 1.6M | 3.1% | 13F |
Insiders
- ZERBE ROBERT L MDDirector
- Flynn Sean C.Chief Legal Officer
- SIEGAL JONATHANPrincipal Accounting Officer
- MCLAUGHLIN KEVIN FDirector
- Halpin MichaelChief Operating Officer
- Hopper Jonathan MarkChief Medical Officer
- Wotton Paul KDirector
- Mara Joseph Anthony JrChief Financial Officer
- Rubino Alan LDirector
- WRIGHT LISADirector
Top institutional holders
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments.
Its primary therapeutic areas are sports medicine and critical burn care across the United States.
The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children.
Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
13F filers report 55.76M shares, more than the 51.03M outstanding, so no percentage is shown. 13F reports lag by a quarter and shares lent to short sellers can be counted twice.
US30d Avg
772.59K
60d Avg
669.28K
90d Avg
600.59K